Cyclin B2 Rabbit Pab

Total Page：16

File Type：pdf, Size：1020Kb

Leader in Biomolecular Solutions for Life Science Cyclin B2 Rabbit pAb Catalog No.: A3351 2 Publications Basic Information Background Catalog No. Cyclin B2 is a member of the cyclin family, specifically the B-type cyclins. The B-type A3351 cyclins, B1 and B2, associate with p34cdc2 and are essential components of the cell cycle regulatory machinery. B1 and B2 differ in their subcellular localization. Cyclin B1 Observed MW co-localizes with microtubules, whereas cyclin B2 is primarily associated with the Golgi 45kDa region. Cyclin B2 also binds to transforming growth factor beta RII and thus cyclin B2/cdc2 may play a key role in transforming growth factor beta-mediated cell cycle Calculated MW control. 45kDa Category Primary antibody Applications WB, IHC Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 9133 O95067 IHC 1:100 - 1:200 Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 1-100 of human Cyclin B2 (NP_004692.1). Synonyms CCNB2;HsT17299;cyclin B2 Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using Cyclin B2 antibody (A3351) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 30s. Antibody | Protein | ELISA Kits | Enzyme | NGS | Service For research use only. Not for therapeutic or diagnostic purposes. Please visit http://abclonal.com for a complete listing of recommended products..

Copy Link

Recommended publications

Nerve Growth Factor Induces Transcription of the P21 WAF1/CIP1 and Cyclin D1 Genes in PC12 Cells by Activating the Sp1 Transcription Factor
The Journal of Neuroscience, August 15, 1997, 17(16):6122–6132 Nerve Growth Factor Induces Transcription of the p21 WAF1/CIP1 and Cyclin D1 Genes in PC12 Cells by Activating the Sp1 Transcription Factor Guo-Zai Yan and Edward B. Ziff Howard Hughes Medical Institute, Department of Biochemistry, Kaplan Cancer Center, New York University Medical Center, New York, New York 10016 The PC12 pheochromocytoma cell line responds to nerve in which the Gal4 DNA binding domain is fused to the Sp1 growth factor (NGF) by gradually exiting from the cell cycle and transactivation domain, indicating that this transactivation do- differentiating to a sympathetic neuronal phenotype. We have main is regulated by NGF. Epidermal growth factor, which is a shown previously (Yan and Ziff, 1995) that NGF induces the weak mitogen for PC12, failed to induce any of these promoter expression of the p21 WAF1/CIP1/Sdi1 (p21) cyclin-dependent constructs. We consider a model in which the PC12 cell cycle kinase (Cdk) inhibitor protein and the G1 phase cyclin, cyclin is arrested as p21 accumulates and attains inhibitory levels D1. In this report, we show that induction is at the level of relative to Cdk/cyclin complexes. Sustained activation of p21 transcription and that the DNA elements in both promoters that expression is proposed to be a distinguishing feature of the are required for NGF-speciﬁc induction are clusters of binding activity of NGF that contributes to PC12 growth arrest during sites for the Sp1 transcription factor. NGF also induced a differentiation synthetic
[Show full text]
Role of Cyclin-Dependent Kinase 1 in Translational Regulation in the M-Phase
cells Review Role of Cyclin-Dependent Kinase 1 in Translational Regulation in the M-Phase Jaroslav Kalous *, Denisa Jansová and Andrej Šušor Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Rumburska 89, 27721 Libechov, Czech Republic; [email protected] (D.J.); [email protected] (A.Š.) * Correspondence: [email protected] Received: 28 April 2020; Accepted: 24 June 2020; Published: 27 June 2020 Abstract: Cyclin dependent kinase 1 (CDK1) has been primarily identified as a key cell cycle regulator in both mitosis and meiosis. Recently, an extramitotic function of CDK1 emerged when evidence was found that CDK1 is involved in many cellular events that are essential for cell proliferation and survival. In this review we summarize the involvement of CDK1 in the initiation and elongation steps of protein synthesis in the cell. During its activation, CDK1 influences the initiation of protein synthesis, promotes the activity of specific translational initiation factors and affects the functioning of a subset of elongation factors. Our review provides insights into gene expression regulation during the transcriptionally silent M-phase and describes quantitative and qualitative translational changes based on the extramitotic role of the cell cycle master regulator CDK1 to optimize temporal synthesis of proteins to sustain the division-related processes: mitosis and cytokinesis. Keywords: CDK1; 4E-BP1; mTOR; mRNA; translation; M-phase 1. Introduction 1.1. Cyclin Dependent Kinase 1 (CDK1) Is a Subunit of the M Phase-Promoting Factor (MPF) CDK1, a serine/threonine kinase, is a catalytic subunit of the M phase-promoting factor (MPF) complex which is essential for cell cycle control during the G1-S and G2-M phase transitions of eukaryotic cells.
[Show full text]
Correction1 4784..4785
Correction Correction: PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis In the article on PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis published in the May 15, 2009 issue of Clinical Cancer Research, there was an error in Table 1. Down-regulated genes were incorrectly labeled as up-regulated genes. The correct table appears here. Bhalla S, Balasubramanian S, David K, et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-nB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 2009;15:3354–65. Table 1. Selected genes from expression analysis following 24-h treatment with PCI-24781, bortezomib, or the combination (in Ramos cells) Accn # Down-regulated genes 0.25 Mmol/L PCI/3 nmol/L Bor Name PCI-24781 Bortezomib Combination* Cell cycle-related NM_000075 Cyclin-dependent kinase 4 (CDK4) 0.49 0.83 0.37 NM_001237 Cyclin A2 (CCNA2) 0.43 0.87 0.37 NM_001950 E2F transcription factor 4, p107/p130-binding (E2F4) 0.48 0.79 0.40 NM_001951 E2F transcription factor 5, p130-binding (E2F5) 0.46 0.98 0.43 NM_003903 CDC16 cell division cycle 16 homolog (S cerevisiae) (CDC16) 0.61 0.78 0.43 NM_031966 Cyclin B1 (CCNB1) 0.55 0.90 0.43 NM_001760 Cyclin D3 (CCND3) 0.48 1.02 0.46 NM_001255 CDC20 cell division cycle 20 homolog (S cerevisiae; CDC20) 0.61 0.82 0.46 NM_001262 Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4; CDKN2C) 0.61 1.15 0.56 NM_001238 Cyclin E1 (CCNE1) 0.56 1.05 0.60 NM_001239 Cyclin H (CCNH) 0.74 0.90 0.64 NM_004701
[Show full text]
The Localization of Human Cyclins B1 and B2 Determines CDK1
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central The Localization of Human Cyclins B1 and B2 Determines CDK1 Substrate Specificity and Neither Enzyme Requires MEK to Disassemble the Golgi Apparatus Viji Mythily Draviam,* Simona Orrechia,‡ Martin Lowe,§ Ruggero Pardi,‡ and Jonathon Pines* *Wellcome/Cancer Research Campaign Institute and Department of Zoology, Cambridge CB2 1QR, United Kingdom; ‡Vita Salute University School of Medicine, Scientiﬁc Institute San Raffaele, Milan I-20132, Italy; and §Division of Biochemistry, School of Biological Sciences, University of Manchester, Manchester M13 9PT, United Kingdom Abstract. In this paper, we show that substrate speciﬁcity confer upon it the more limited properties of cyclin B2. is primarily conferred on human mitotic cyclin-dependent Equally, directing cyclin B2 to the cytoplasm with the kinases (CDKs) by their subcellular localization. The NH2 terminus of cyclin B1 confers the broader properties difference in localization of the B-type cyclin–CDKs of cyclin B1. Furthermore, we show that the disassembly underlies the ability of cyclin B1–CDK1 to cause chromo- of the Golgi apparatus initiated by either mitotic cyclin– some condensation, reorganization of the microtubules, CDK complex does not require mitogen-activated and disassembly of the nuclear lamina and of the Golgi protein kinase kinase (MEK) activity. apparatus, while it restricts cyclin B2–CDK1 to disassem- bly of the Golgi apparatus. We identify the region of Key words: cyclin • CDK • mitosis • protein kinase • cyclin B2 responsible for its localization and show that Golgi apparatus this will direct cyclin B1 to the Golgi apparatus and Introduction Cyclins play a vital role in controlling progress through the or mitosis (M phase) depending on the amount of kinase eukaryotic cell cycle.
[Show full text]
Cyclin a Triggers Mitosis Either Via Greatwall Or Cyclin B
bioRxiv preprint doi: https://doi.org/10.1101/501684; this version posted December 20, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cyclin A triggers Mitosis either via Greatwall or Cyclin B Nadia Hégarat(1)*, Adrijana Crncec(1)*, Maria F. Suarez Peredoa Rodri- guez(1), Fabio Echegaray Iturra(1), Yan Gu(1), Paul F. Lang(2), Alexis R. Barr(3), Chris Bakal(4), Masato T. Kanemaki(5), Angus I. Lamond(6), Bela Novak(2), Tony Ly(7)•• and Helfrid Hochegger(1)•• (1) Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Brighton BN19RQ, UK (2) Department of Biochemistry, University of Oxford, South Park Road, Oxford OX13QU, UK (3) MRC London Institute of Medical Science, Imperial College, London W12 0NN, UK (4) The Institute of Cancer Research, London SW3 6JB, UK (5) National Institute of Genetics, Research Organization of Information and Sys- tems (ROIS), and Department of Genetics, SOKENDAI (The Graduate University of Advanced Studies), Yata 1111, Mishima, Shizuoka 411-8540, Japan. (6) Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK (7) Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, UK * Equal contribution ** Correspondence: Tony Ly: [email protected]; Helfrid Hochegger: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/501684; this version posted December 20, 2018.
[Show full text]
The Genetic Program of Pancreatic Beta-Cell Replication in Vivo
Page 1 of 65 Diabetes The genetic program of pancreatic beta-cell replication in vivo Agnes Klochendler1, Inbal Caspi2, Noa Corem1, Maya Moran3, Oriel Friedlich1, Sharona Elgavish4, Yuval Nevo4, Aharon Helman1, Benjamin Glaser5, Amir Eden3, Shalev Itzkovitz2, Yuval Dor1,* 1Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 2Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 3Department of Cell and Developmental Biology, The Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel 4Info-CORE, Bioinformatics Unit of the I-CORE Computation Center, The Hebrew University and Hadassah, The Institute for Medical Research Israel- Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 5Endocrinology and Metabolism Service, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel *Correspondence: [email protected] Running title: The genetic program of pancreatic β-cell replication 1 Diabetes Publish Ahead of Print, published online March 18, 2016 Diabetes Page 2 of 65 Abstract The molecular program underlying infrequent replication of pancreatic beta- cells remains largely inaccessible. Using transgenic mice expressing GFP in cycling cells we sorted live, replicating beta-cells and determined their transcriptome. Replicating beta-cells upregulate hundreds of proliferation- related genes, along with many novel putative cell cycle components. Strikingly, genes involved in beta-cell functions, namely glucose sensing and insulin secretion were repressed. Further studies using single molecule RNA in situ hybridization revealed that in fact, replicating beta-cells double the amount of RNA for most genes, but this upregulation excludes genes involved in beta-cell function.
[Show full text]
Targeting Cyclin-Dependent Kinases in Human Cancers: from Small Molecules to Peptide Inhibitors
Cancers 2015, 7, 179-237; doi:10.3390/cancers7010179 OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Review Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors Marion Peyressatre †, Camille Prével †, Morgan Pellerano and May C. Morris * Institut des Biomolécules Max Mousseron, IBMM-CNRS-UMR5247, 15 Av. Charles Flahault, 34093 Montpellier, France; E-Mails: [email protected] (M.P.); [email protected] (C.P.); [email protected] (M.P.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +33-04-1175-9624; Fax: +33-04-1175-9641. Academic Editor: Jonas Cicenas Received: 17 December 2014 / Accepted: 12 January 2015 / Published: 23 January 2015 Abstract: Cyclin-dependent kinases (CDK/Cyclins) form a family of heterodimeric kinases that play central roles in regulation of cell cycle progression, transcription and other major biological processes including neuronal differentiation and metabolism. Constitutive or deregulated hyperactivity of these kinases due to amplification, overexpression or mutation of cyclins or CDK, contributes to proliferation of cancer cells, and aberrant activity of these kinases has been reported in a wide variety of human cancers. These kinases therefore constitute biomarkers of proliferation and attractive pharmacological targets for development of anticancer therapeutics. The structural features of several of these kinases have been elucidated and their molecular mechanisms of regulation characterized in depth, providing clues for development of drugs and inhibitors to disrupt their function. However, like most other kinases, they constitute a challenging class of therapeutic targets due to their highly conserved structural features and ATP-binding pocket.
[Show full text]
Supplementary Figure 1 Sag Et Al
Supplementary figure 1 Sag et al. A B Promotes cell cycle progression Inhibits cell cycle progression Marker Gene name αGC-pre/B6 Marker Gene name αGC-pre/B6 Ki67 Mki67 7.75 p21Cip1 (cyclin-dependent kinase Aurora kinase B Aurkb 8.09 inhibitor 1A (P21)) Cdkn1a -1.81 budding uninhibited by p27Kip1 (cyclin-dependent kinase benzimidazoles 1 homolog (yeast) Bub1 6.56 inhibitor 1B) Cdkn1b -1.13 Cyclin A2 Ccna2 8.8 p57Kip (cyclin-dependent kinase Cyclin B1 Ccnb1 9.7 inhibitor 1C (P57)) Cdkn1c n.ex. Cyclin B2 Ccnb2 9.92 p16Ink4a (cyclin-dependent kinase Cyclin E1 Ccne1 4.29 inhibitor 2A) Cdkn2a n.ex. Cyclin F Ccnf 8.26 p15Ink4b (cyclin-dependent kinase Coiled coil domain containing 28B Ccdc28b 3.02 inhibitor 2B (p15) Cdkn2b n.ex. Coiled-coil domain containing 109B Ccdc109b 38.48 p18Ink4c (cyclin-dependent kinase Cyclin-dependent kinase 1 Cdk1 8.01 inhibitor 2C (p18) Cdkn2c 2.34 Cell division cycle 6 Cdc6 5.88 p19Ink4d (cyclin-dependent kinase Cell division cycle 20 Cdc20 3.51 inhibitor 2D (p19) Cdkn2d 2.23 Cell division cycle 25b Cdc25b 5 CDC42 effector protein 4 Cdc42ep4 6.02 Cell division cycle 45 Cdc45 3.34 Cell division cycle associated 2 Cdca2 6.19 Cell division cycle associated 3 Cdca3 7.38 Cell division cycle associated 5 Cdca5 5 Cell division cycle associated 8 Cdca8 6.35 Claspin Clspn 7.06 establishment of cohesion 1 homolog 2 (S. cerevisiae) Esco2 7.79 RAD51 associated protein 1 Rad51ap1 6.54 TPX2, microtubule-associated, homolog (Xenopus laevis) Tpx2 7.68 Supplementary figure 1.
[Show full text]
Cell Cycle Control by Xenopus P28kixl a Developmentally Regulated Inhibitor of Cyclin-Dependent Kinases Wenying Shou and William G
Molecular Biology of the Cell Vol. 7, 457-469, March 1996 Cell Cycle Control by Xenopus p28Kixl a Developmentally Regulated Inhibitor of Cyclin-dependent Kinases Wenying Shou and William G. Dunphy* Division of Biology 216-76, Howard Hughes Medical Institute, California Institute of Technology, Pasadena, California 91125 Submitted October 19, 1995; Accepted December 15, 1995 Monitoring Editor: Tim Hunt We have isolated Xenopus p28Kixl, a member of the p21CIPl/p27KIPI /p57KIP2 family of cyclin-dependent kinase (Cdk) inhibitors. Members of this family negatively regulate cell cycle progression in mammalian cells by inhibiting the activities of Cdks. p28 shows significant sequence homology with p21, p27, and p57 in its N-terminal region, where the Cdk inhibition domain is known to reside. In contrast, the C-terminal domain of p28 is distinct from that of p21, p27, and p57. In co-immunoprecipitation experiments, p28 was found to be associated with Cdk2, cyclin E, and cyclin A, but not the Cdc2/cyclin B complex in Xenopus egg extracts. Xenopus p28 associates with the proliferating cell nuclear antigen, but with a substantially lower affinity than human p21. In kinase assays with recombinant Cdks, p28 inhibits pre-activated Cdk2/cyclin E and Cdk2/cyclin A, but not Cdc2/cyclin B. However, at high concentrations, p28 does prevent the activation of Cdc2/cyclin B by the Cdk-activating kinase. Consistent with the role of p28 as a Cdk inhibitor, recombinant p28 elicits an inhibition of both DNA replication and mitosis upon addition to egg extracts, indicating that it can regulate multiple cell cycle transitions. The level of p28 protein shows a dramatic developmental profile: it is low in Xenopus oocytes, eggs, and embryos up to stage 11, but increases -100-fold between stages 12 and 13, and remains high thereafter.
[Show full text]
Effects of Flavonoids on Expression of Genes Involved in Cell Cycle
Mol Cell Biochem (2015) 407:97–109 DOI 10.1007/s11010-015-2458-3 Effects of flavonoids on expression of genes involved in cell cycle regulation and DNA replication in human fibroblasts 1 2 2 Marta Moskot • Joanna Jako´bkiewicz-Banecka • Elwira Smolin´ska • 2 2 1 Ewa Piotrowska • Grzegorz We˛grzyn • Magdalena Gabig-Cimin´ska Received: 16 January 2015 / Accepted: 16 May 2015 / Published online: 24 May 2015 Ó The Author(s) 2015. This article is published with open access at Springerlink.com Abstract Flavonoids have been studied as potential accompanied by activation of CDKN1A, CDKN1C, agents in medicine for many years. Among them, genistein CDKN2A, CDKN2B, CDKN2C, and GADD45A genes, as was found to be active in various biological systems, well as down-regulation of several mRNAs specific for this mainly in prevention of cancer. Our recent work supported stage, demonstrated by transcriptomic assessments. We the idea that genistein also impacts multiple cellular pro- believe that studies described in this paper will be helpful cesses in healthy fibroblasts; however, its effects on cell in elucidating molecular mechanisms of action of genistein cycle-related pathways remained to be elucidated. Thus, in as modulator of cell cycle and inhibitor of DNA replication this work, high throughput screening with microarrays in humans. coupled to real-time quantitative Reverse Transcription PCR analyses was employed to study the changes in ex- Keywords Flavonoids Á Cell cycle regulation Á DNA pression of key genes associated with cell cycle regulation replication process Á Gene expression profiling Á Cell and/or DNA replication in response to genistein, growth kaempferol, daidzein, and mixtures of genistein and either kaempferol or daidzein.
[Show full text]
Cell Cycle Arrest Through Indirect Transcriptional Repression by P53: I Have a DREAM
Cell Death and Differentiation (2018) 25, 114–132 Ofﬁcial journal of the Cell Death Differentiation Association OPEN www.nature.com/cdd Review Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM Kurt Engeland1 Activation of the p53 tumor suppressor can lead to cell cycle arrest. The key mechanism of p53-mediated arrest is transcriptional downregulation of many cell cycle genes. In recent years it has become evident that p53-dependent repression is controlled by the p53–p21–DREAM–E2F/CHR pathway (p53–DREAM pathway). DREAM is a transcriptional repressor that binds to E2F or CHR promoter sites. Gene regulation and deregulation by DREAM shares many mechanistic characteristics with the retinoblastoma pRB tumor suppressor that acts through E2F elements. However, because of its binding to E2F and CHR elements, DREAM regulates a larger set of target genes leading to regulatory functions distinct from pRB/E2F. The p53–DREAM pathway controls more than 250 mostly cell cycle-associated genes. The functional spectrum of these pathway targets spans from the G1 phase to the end of mitosis. Consequently, through downregulating the expression of gene products which are essential for progression through the cell cycle, the p53–DREAM pathway participates in the control of all checkpoints from DNA synthesis to cytokinesis including G1/S, G2/M and spindle assembly checkpoints. Therefore, defects in the p53–DREAM pathway contribute to a general loss of checkpoint control. Furthermore, deregulation of DREAM target genes promotes chromosomal instability and aneuploidy of cancer cells. Also, DREAM regulation is abrogated by the human papilloma virus HPV E7 protein linking the p53–DREAM pathway to carcinogenesis by HPV.Another feature of the pathway is that it downregulates many genes involved in DNA repair and telomere maintenance as well as Fanconi anemia.
[Show full text]
Regulation of the Retinoblastoma Protein-Related Protein P107 by G1 Cyclin-Associated Kinases ZHI-XIONG XIAO, DORON GINSBERG, MARK EWEN, and DAVID M
Proc. Natl. Acad. Sci. USA Vol. 93, pp. 4633-4637, May 1996 Cell Biology This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected on April 25, 1995. Regulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases ZHI-XIONG XIAO, DORON GINSBERG, MARK EWEN, AND DAVID M. LIVINGSTON* Dlna-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115 Conitribulted by David M. Livingston, Febriary 15, 1996 ABSTRACT p107 is a retinoblastoma protein-related cyclin D plays an essential role in GI exit only when cells phosphoprotein that, when overproduced, displays a growth synthesize intact pRB (14, 15). inhibitory function. It interacts with and modulates the ac- Phosphorylated p107 contains both phosphoserine and tivity of the transcription factor, E2F-4. In addition, p107 phosphothreonine residues (16). Its pocket and C-terminal physically associates with cyclin E-CDK2 and cyclin A-CDK2 segment, like the analogous segments of pRB, can bind cyclin complexes in late GI and at GI/S, respectively, an indication D in vitro (17). Given that pRB phosphorylation is initiated by that cyclin-dependent kinase complexes may regulate, con- cyclin D/kinase (13) and that pRB phosphorylation has pro- tribute to, and/or benefit from p107 function during the cell found effects on its function, one wonders whether cyclin cycle. Our results show that p107 phosphorylation begins in D/kinase acts similarly on p107. In this report, we show that mid GI and proceeds through late GI and S and that cyclin p107 is phosphorylated in a cell cycle-dependent manner.
[Show full text]